XIDX
TSPC
Market cap738mUSD
Nov 12, Last price
2,930.00IDR
Name
Tempo Scan Pacific Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Tempo Scan Pacific Tbk, an Indonesian company headquartered in Jakarta with an international presence, operates primarily across three core business segments: pharmaceuticals, consumer products and cosmetics, and distribution services. Its activities encompass the trading of pharmaceutical and medical devices, alongside the manufacturing of diverse goods such as soaps, herbal products, powdered milk, food and beverages, and plastic packaging. The company also produces and markets a variety of consumer goods, cosmetic lines, and household items. Products are sold under an extensive portfolio of brands, including Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, MY BABY, MY BABY Kids, Pure Baby, S.O.S, Total Care, and ULTIMA II. Beyond these, PT Tempo Scan Pacific Tbk offers a range of supplementary services, including property construction and leasing, warehousing and freight forwarding, advertising and promotion, research and development, and information technology and communication network systems. It also manages procurement, distribution, and marketing functions. Established in 1970, the company was formerly known as PT Scanchemie and functions as a subsidiary of PT Bogamulia Nagadi.
Key people
Dian Paramita Tamzil
President Commissioner · since 1995
Phillips Gunawan
Director · since 2019
Rorita Lim
Director · since 2019
Linda Lukitasari
Director · since 2015
Dondi Sapto Margono
Director · since 1998
Liza Prasodjo
Director · since 2012
Hartaty Susanto
Director · since 2012
Prayoga Wahyudianto
Director · since 2016
I. Made Dharma Wijaya
Director · since 2018
Shania
Independent Director, Corporate Secretary · since 2017
Olga Asihjati Adjiputro Wijaya
Independent Commissioner · since 1997
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||